CYTK
insider transactionsCYTOKINETICS INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-187.6K
0 buy · 187.6K sell
Net value · 90d
-$13.4M
$0 in · $13.4M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
23
0 buy · 187.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Robert I Blum KEY
President & CEO · 10b5-1
$528.5K
7.5K sh · $70.46
Own -2%
-
Exercise·M
EVP Research & Development · 10b5-1
$0
3.5K sh
Own +9%
-
Sell·S
EVP Research & Development · 10b5-1
$237.9K
3.5K sh · $67.98
Own -2%
-
Exercise·M
EVP Research & Development · 10b5-1
$27.3K
3.5K sh · $7.80
Own +2%
-
Sell·S
Director · 10b5-1
$223.2K
2.9K sh · $76.09
Own -22%
-
Exercise·M
EVP, Chief Commercial Officer · 10b5-1
$0
15.0K sh
Own +62%
-
Sell·S
EVP, Chief Commercial Officer · 10b5-1
$1.1M
15.0K sh · $74.08
Own -20%
-
Exercise·M
EVP, Chief Commercial Officer · 10b5-1
$348.9K
15.0K sh · $23.26
Own +26%
-
Sell·S
Director · 10b5-1
$370.4K
5.0K sh · $74.08
Own -24%
-
Grant·A
Director
$0
4.3K sh
Own New
-
Grant·A
Director
$0
2.9K sh
Own +735%
-
Grant·A
Director
$0
4.3K sh
Own New
-
Grant·A
Director
$0
2.9K sh
Own +15%
-
Grant·A
Director
$0
4.3K sh
Own New
-
Grant·A
Director
$0
2.9K sh
Own +4%
-
Grant·A
Director
$0
4.3K sh
Own New
-
Grant·A
Director
$0
2.9K sh
Own +28%
-
Grant·A
Director
$0
4.3K sh
Own New
-
Grant·A
Director
$0
2.9K sh
Own +16%
-
Grant·A
Director
$0
4.3K sh
Own New
-
Grant·A
Director
$0
2.9K sh
Own +39%
-
Grant·A
Director
$0
4.3K sh
Own New
-
Grant·A
Director
$0
2.9K sh
Own +9%
-
Grant·A
Director
$0
4.3K sh
Own New
-
Grant·A
Director
$0
2.9K sh
Own +9%
-
Sell·S
Robert I Blum KEY
President & CEO · 10b5-1
$579.1K
7.5K sh · $77.21
Own -2%
-
Exercise·M
EVP Research & Development · 10b5-1
$0
3.5K sh
Own +8%
-
Sell·S
EVP Research & Development · 10b5-1
$264.9K
3.5K sh · $75.69
Own -2%
-
Exercise·M
EVP Research & Development · 10b5-1
$27.3K
3.5K sh · $7.80
Own +2%
-
Sell·S
Robert I Blum KEY
President & CEO · 10b5-1
$584.4K
7.5K sh · $77.92
Own -2%
-
Exercise·M
EVP Research & Development · 10b5-1
$0
3.5K sh
Own +7%
-
Sell·S
EVP Research & Development · 10b5-1
$270.8K
3.5K sh · $77.37
Own -2%
-
Exercise·M
EVP Research & Development · 10b5-1
$27.3K
3.5K sh · $7.80
Own +2%
-
Exercise·M
Director · 10b5-1
$0
4.0K sh
Own New
-
Sell·S
Director · 10b5-1
$302.4K
4.0K sh · $75.00
Own -11%
-
Exercise·M
Director · 10b5-1
$50.0K
4.0K sh · $12.40
Own +12%
-
Sell·S
Sung Lee KEY
EVP, Chief Financial Officer · 10b5-1
$1.8M
23.9K sh · $76.87
Own -27%
-
Exercise·M
Director · 10b5-1
$0
20.0K sh
Own New
-
Sell·S
Director · 10b5-1
$1.5M
20.0K sh · $75.97
Own -21%
-
Exercise·M
Director · 10b5-1
$152.2K
20.0K sh · $7.61
Own +27%
-
Exercise·M
EVP, Chief Commercial Officer · 10b5-1
$0
11.3K sh
Own +652%
-
Sell·S
EVP, Chief Commercial Officer · 10b5-1
$875.5K
11.3K sh · $77.25
Own -16%
-
Exercise·M
EVP, Chief Commercial Officer · 10b5-1
$443.5K
11.3K sh · $39.13
Own +19%
-
Exercise·M
EVP, Chief Commercial Officer · 10b5-1
$0
15.9K sh
Own New
-
Sell·S
EVP, Chief Commercial Officer · 10b5-1
$1.0M
15.9K sh · $65.00
Own -21%
-
Exercise·M
EVP, Chief Commercial Officer · 10b5-1
$596.7K
15.9K sh · $37.63
Own +27%
-
Exercise·M
EVP, Chief Commercial Officer · 10b5-1
$0
15.0K sh
Own +38%
-
Sell·S
EVP, Chief Commercial Officer · 10b5-1
$948.9K
15.0K sh · $63.26
Own -20%
-
Exercise·M
EVP, Chief Commercial Officer · 10b5-1
$348.9K
15.0K sh · $23.26
Own +26%
-
Sell·S
Robert I Blum KEY
President & CEO · 10b5-1
$447.1K
7.5K sh · $59.62
Own -2%
-
Exercise·M
EVP Research & Development · 10b5-1
$0
3.5K sh
Own +7%
-
Sell·S
EVP Research & Development · 10b5-1
$229.9K
3.5K sh · $65.69
Own -2%
-
Exercise·M
EVP Research & Development · 10b5-1
$27.3K
3.5K sh · $7.80
Own +2%
-
Grant·A
Director
$6.2K
95 sh · $65.37
Own +0%
-
Grant·A
Director
$6.2K
95 sh · $65.37
Own +0%
-
Grant·A
Director
$12.5K
191 sh · $65.37
Own +2%
-
Grant·A
Director
$21.2K
325 sh · $65.37
Own +0%
-
Grant·A
Director
$12.5K
191 sh · $65.37
Own +1%
-
Grant·A
Director
$12.5K
191 sh · $65.37
Own +97%
-
Sell·S
EVP, Chief Commercial Officer · 10b5-1
$491.8K
7.4K sh · $66.02
Own -11%
-
Sell·S
Robert I Blum KEY
President & CEO · 10b5-1
$490.4K
7.5K sh · $65.38
Own -2%
-
Exercise·M
EVP Research & Development · 10b5-1
$0
1.0K sh
Own New
-
Exercise·M
EVP Research & Development · 10b5-1
$0
3.5K sh
Own +6%
-
Sell·S
EVP Research & Development · 10b5-1
$64.8K
1.0K sh · $64.75
Own -1%
-
Exercise·M
EVP Research & Development · 10b5-1
$10.6K
1.0K sh · $10.60
Own +1%
-
Sell·S
EVP Research & Development · 10b5-1
$228.2K
3.5K sh · $65.21
Own -2%
-
Exercise·M
EVP Research & Development · 10b5-1
$27.3K
3.5K sh · $7.80
Own +2%
-
Sell·S
Robert I Blum KEY
President & CEO · 10b5-1
$499.7K
7.5K sh · $66.63
Own -2%
-
Sell·S
EVP, Chief Commercial Officer · 10b5-1
$236.5K
3.6K sh · $65.00
Own -5%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Robert I Blum KEY 10b5-1 | Sell S | 7.5K | $528.5K |
| Jun 9, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 3.5K | $0 |
| Jun 9, 2026 | Fady Ibraham Malik 10b5-1 | Sell S | 3.5K | $237.9K |
| Jun 9, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 3.5K | $27.3K |
| Jun 1, 2026 | Edward M. Kaye MD 10b5-1 | Sell S | 2.9K | $223.2K |
| Jun 1, 2026 | Andrew Callos 10b5-1 | Exercise M | 15.0K | $0 |
| Jun 1, 2026 | Andrew Callos 10b5-1 | Sell S | 15.0K | $1.1M |
| Jun 1, 2026 | Andrew Callos 10b5-1 | Exercise M | 15.0K | $348.9K |
| Jun 1, 2026 | Lynne B Parshall 10b5-1 | Sell S | 5.0K | $370.4K |
| May 27, 2026 | James M Daly | Grant A | 4.3K | $0 |
| May 27, 2026 | James M Daly | Grant A | 2.9K | $0 |
| May 27, 2026 | Robert Arthur Harrington | Grant A | 4.3K | $0 |
| May 27, 2026 | Robert Arthur Harrington | Grant A | 2.9K | $0 |
| May 27, 2026 | John T Henderson | Grant A | 4.3K | $0 |
| May 27, 2026 | John T Henderson | Grant A | 2.9K | $0 |
| May 27, 2026 | Edward M. Kaye MD | Grant A | 4.3K | $0 |
| May 27, 2026 | Edward M. Kaye MD | Grant A | 2.9K | $0 |
| May 27, 2026 | Lynne B Parshall | Grant A | 4.3K | $0 |
| May 27, 2026 | Lynne B Parshall | Grant A | 2.9K | $0 |
| May 27, 2026 | Robert E Landry | Grant A | 4.3K | $0 |
| May 27, 2026 | Robert E Landry | Grant A | 2.9K | $0 |
| May 27, 2026 | Wendell Wierenga | Grant A | 4.3K | $0 |
| May 27, 2026 | Wendell Wierenga | Grant A | 2.9K | $0 |
| May 27, 2026 | Nancy Wysenski | Grant A | 4.3K | $0 |
| May 27, 2026 | Nancy Wysenski | Grant A | 2.9K | $0 |
| May 27, 2026 | Robert I Blum KEY 10b5-1 | Sell S | 7.5K | $579.1K |
| May 19, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 3.5K | $0 |
| May 19, 2026 | Fady Ibraham Malik 10b5-1 | Sell S | 3.5K | $264.9K |
| May 19, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 3.5K | $27.3K |
| May 14, 2026 | Robert I Blum KEY 10b5-1 | Sell S | 7.5K | $584.4K |
| May 5, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 3.5K | $0 |
| May 5, 2026 | Fady Ibraham Malik 10b5-1 | Sell S | 3.5K | $270.8K |
| May 5, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 3.5K | $27.3K |
| May 5, 2026 | Wendell Wierenga 10b5-1 | Exercise M | 4.0K | $0 |
| May 5, 2026 | Wendell Wierenga 10b5-1 | Sell S | 4.0K | $302.4K |
| May 5, 2026 | Wendell Wierenga 10b5-1 | Exercise M | 4.0K | $50.0K |
| May 5, 2026 | Sung Lee KEY 10b5-1 | Sell S | 23.9K | $1.8M |
| May 5, 2026 | John T Henderson 10b5-1 | Exercise M | 20.0K | $0 |
| May 5, 2026 | John T Henderson 10b5-1 | Sell S | 20.0K | $1.5M |
| May 5, 2026 | John T Henderson 10b5-1 | Exercise M | 20.0K | $152.2K |
| May 5, 2026 | Andrew Callos 10b5-1 | Exercise M | 11.3K | $0 |
| May 5, 2026 | Andrew Callos 10b5-1 | Sell S | 11.3K | $875.5K |
| May 5, 2026 | Andrew Callos 10b5-1 | Exercise M | 11.3K | $443.5K |
| May 1, 2026 | Andrew Callos 10b5-1 | Exercise M | 15.9K | $0 |
| May 1, 2026 | Andrew Callos 10b5-1 | Sell S | 15.9K | $1.0M |
| May 1, 2026 | Andrew Callos 10b5-1 | Exercise M | 15.9K | $596.7K |
| Apr 30, 2026 | Andrew Callos 10b5-1 | Exercise M | 15.0K | $0 |
| Apr 30, 2026 | Andrew Callos 10b5-1 | Sell S | 15.0K | $948.9K |
| Apr 30, 2026 | Andrew Callos 10b5-1 | Exercise M | 15.0K | $348.9K |
| Apr 29, 2026 | Robert I Blum KEY 10b5-1 | Sell S | 7.5K | $447.1K |
| Apr 21, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 3.5K | $0 |
| Apr 21, 2026 | Fady Ibraham Malik 10b5-1 | Sell S | 3.5K | $229.9K |
| Apr 21, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 3.5K | $27.3K |
| Apr 15, 2026 | Nancy Wysenski | Grant A | 95 | $6.2K |
| Apr 15, 2026 | Wendell Wierenga | Grant A | 95 | $6.2K |
| Apr 15, 2026 | Edward M. Kaye MD | Grant A | 191 | $12.5K |
| Apr 15, 2026 | John T Henderson | Grant A | 325 | $21.2K |
| Apr 15, 2026 | Robert Arthur Harrington | Grant A | 191 | $12.5K |
| Apr 15, 2026 | James M Daly | Grant A | 191 | $12.5K |
| Apr 15, 2026 | Andrew Callos 10b5-1 | Sell S | 7.4K | $491.8K |
| Apr 15, 2026 | Robert I Blum KEY 10b5-1 | Sell S | 7.5K | $490.4K |
| Apr 7, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 1.0K | $0 |
| Apr 7, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 3.5K | $0 |
| Apr 7, 2026 | Fady Ibraham Malik 10b5-1 | Sell S | 1.0K | $64.8K |
| Apr 7, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 1.0K | $10.6K |
| Apr 7, 2026 | Fady Ibraham Malik 10b5-1 | Sell S | 3.5K | $228.2K |
| Apr 7, 2026 | Fady Ibraham Malik 10b5-1 | Exercise M | 3.5K | $27.3K |
| Apr 1, 2026 | Robert I Blum KEY 10b5-1 | Sell S | 7.5K | $499.7K |
| Mar 31, 2026 | Andrew Callos 10b5-1 | Sell S | 3.6K | $236.5K |
About CYTK insider trading
This page tracks insider transactions for CYTOKINETICS INC (CYTK) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.